(Q35642546)

9 August 2017

title

An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures (English)

1 reference

9 August 2017

1 reference

Madeline Betancourt

1

1 reference

9 August 2017

Peggy S McKinnon

2

1 reference

9 August 2017

R Michael Massanari

3

1 reference

9 August 2017

Salmaan Kanji

4

1 reference

9 August 2017

David Bach

5

1 reference

9 August 2017

John W Devlin

6

1 reference

9 August 2017

publication date

1 January 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

21

1 reference

9 August 2017

issue

18

1 reference

9 August 2017

page(s)

1331-1340

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03262331

9 August 2017

exact match

0 references

cites work

Epidemiology of sepsis syndrome in 8 academic medical centers

1 reference

https://api.crossref.org/works/10.1007%2FBF03262331

Epidemiology of sepsis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262331

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262331

Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262331

Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262331

Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262331

21 January 2018

The protein C pathway

1 reference

https://api.crossref.org/works/10.1007%2FBF03262331

Activated protein C versus protein C in severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262331

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262331

Best practices in the development of clinical practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262331

Pharmacoeconomics and therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262331

The effect of pharmacoeconomics on company research and development decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262331

Pharmacoeconomics: state of the art in 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262331

APACHE II: a severity of disease classification system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262331

The perspective of a pharmacoeconomic study: targeting for audiences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262331

Recent advances in the methods of cost-benefit analysis in healthcare. Matching the art to the science

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262331

At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262331

Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03262331

A clinician's guide to cost-effectiveness analysis

21 January 2018

1 reference

12 December 2020

Applied pharmacoeconomics: evaluation and use of pharmacoeconomic data from the literature.

1 reference

12 December 2020

Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry

1 reference

12 December 2020

Cost effectiveness of HMG-CoA reductase inhibition in Canada

1 reference

12 December 2020

Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase.

1 reference

12 December 2020

Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach

1 reference

12 December 2020

Surgonomics: the cost of gastrointestinal hemorrhage, the identifier concept

1 reference

12 December 2020

A consumer's guide to subgroup analyses

1 reference

12 December 2020

An economic evaluation of activated protein C treatment for severe sepsis

1 reference

12 December 2020

Clinical decisionmaking

1 reference

12 December 2020

The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03262331

1 reference

9 August 2017

1 reference